Duopharma Biotech Berhad (7148.KL)

MYR 1.24

(-0.8%)

Market Cap (In MYR)

1.19 Billion

Revenue (In MYR)

704.72 Million

Net Income (In MYR)

52.64 Million

Avg. Volume

882.08 Thousand

Currency
MYR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.1-1.45
PE
-
EPS
-
Beta Value
0.684
ISIN
MYL7148OO009
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Anas Bin Alam Faizli
Employee Count
-
Website
https://duopharmabiotech.com
Ipo Date
2002-07-19
Details
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products comprising vitamins and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, such as diabetes, cancer, cardiovascular diseases, renal diseases, and others. The company's product portfolio comprises vascor, acetan, covasc, crystorvas, bezartan, vytan, and vytocor; insugen and basalog one; kytron, zuhera, lebreta, trevive, and krabeva; and unihepa, ranofer, erysaa, bi-haemosol, and haemosol. The company offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol brands. In addition, it offers property management and services; and distributes, imports, and exports chemical products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.